ライフサイエンスコーパス: moderate disease

1 therapies (including budesonide for mild to moderate disease).

2 ells and similar low RNA levels (2 patients, moderate disease).

3 se of platelet transfusions (41 with mild or moderate disease).

4 d with the sharp transition between mild and moderate disease.

5 ase of the disease and in patients with mild-moderate disease.

6 acking to inform its effects in infants with moderate disease.

7 ed with patients with asymptomatic, mild, or moderate disease.

8 VID-19 from healthy controls and severe from moderate disease.

9 g may be prudent, even in those with mild to moderate disease.

10 II formula was the most accurate for mild to moderate disease.

11 ype I IFN autoantibodies in individuals with moderate disease.

12 Repeatability of most parameters worsened in moderate disease.

13 nfirmed COVID-19, comorbidities, and mild to moderate disease.

14 disease compared with those of patients with moderate disease.

15 ed fall rates were apparent among those with moderate disease.

16 was 24% for severe periodontitis and 61% for moderate disease.

17 dontitis was better for severe compared with moderate disease.

18 ility to predict the transition from mild to moderate disease.

19 were significantly elevated in patients with moderate disease.

20 e disease had higher viremia than those with moderate disease.

21 ions in this cohort of patients with mild-to-moderate disease.

22 n higher odds of epilepsy compared with mild/moderate disease.

23 even in younger patients and those with only moderate disease.

24 n compared with the prevalence of severe and moderate disease.

25 190 and 541-560, and several others elicited moderate disease.

26 ging from 0.5 to 3, corresponding to mild to moderate disease.

27 thotrexate are effective in treating mild to moderate disease.

28 s factor (TNF)-induced genes was observed in moderate diseases.

29 Disease classification included normal to moderate disease (0%-50% stenosis), severe stenosis (> 5

30 icantly greater extent than in patients with moderate disease (0.018%, P = 0.004).

31 I, 2.9-13.4; p = 0.003) than those with mild/moderate disease (1.6% increase; 95% CI, -2.2-5.4; p = 0

32 There were 60 cases of mild to moderate disease, 148 cases of severe disease, and 79 cr

33 76.5-92.7%]) compared to those with mild or moderate disease (30.7% [95% CI = 21.1-40.9%] and 63.8%

34 Of 787 patients admitted with mild to moderate disease, 302 (38%) progressed to severe disease

35 s had severe disease (>70% stenosis), 12 had moderate disease (50%-70% stenosis), 46 had mild disease

36 (2.7), mild disease -10.2 (18.6), 3.0 (4.1), moderate disease -9.6 (16.6), 4.4 (4.0), severe disease

37 all disease was 78.9% (95% CI, 69.7%-85.3%); moderate disease, 92% (50-500 lesions) and 100% (clinici

38 In children with mild to moderate disease, a reduction of zidovudine to 90 mg/m2/

39 to low disease activity (DAS/DAS28/CDAI) or moderate disease activity (SDAI).

40 f patients receiving MTX monotherapy who had moderate disease activity and a poor prognosis or high d

41 nt was more effective in achieving a good or moderate disease activity response at 24 weeks than was

42 e-escalation study, 16 patients with mild-to-moderate disease activity were assigned to receive 1 of

43 d for 21%, 23%, and 34% of 149 patients with moderate disease activity within 3, 6, and 12 months, re

44 suggests that for this population of mild-to-moderate disease activity, the PDAI captures more variab

45 ts with ulcerative colitis (UC) have mild-to-moderate disease activity, with low risk of colectomy, a

46 ctively, of the patient meeting criteria for moderate disease activity.

47 (83%) were discharged (523 [63%] had mild to moderate disease and 171 [20%] had severe disease).

48 Patients spent a mean of 3.4 years with mild-moderate disease and 3.4 years with severe disease befor

49 Of 1128 children, 371 (32.9%) developed moderate disease and 48 (4.3%) severe disease.

50 to be effective in the treatment of mild to moderate disease and nonsteroidal anti-inflammatory drug

51 In tooth sites with mild to moderate disease and severe disease (n = 183, intent-to-

52 Moderate disease and survival were associated with a str

53 there are no medical consequences to having moderate disease and that disease stage transitions can

54 reased risk of mortality even for those with moderate disease and the inability to predict the transi

55 conclusion, (31)P MRS can separate mild from moderate disease and these 2 groups from cirrhosis.

56 in the immune response in those with mild to moderate disease and those with the most severe disease.

57 ding on probing (slight disease), 3 to 6 mm (moderate disease), and >6 mm (severe disease).

58 AD (20 with mild or limited disease, 17 with moderate disease, and 24 with severe disease) and 20 hea

59 d pulmonary disease, 19% in patients who had moderate disease, and 26% in patients who had severe dis

60 y, 6 (4.6%) had mild disease, 98 (74.8%) had moderate disease, and 27 (20.6%) severe manifestations o

61 (PDE) ratios for the control, mild disease, moderate disease, and cirrhosis groups: 0.15 +/- 0.01, 0

62 we could distinguish between severe disease, moderate disease, and control with rates of correct clas

63 xposure prophylaxis, ambulatory with mild-to-moderate disease, and hospitalized with mild-to-moderate

64 tion or maintenance therapy in patients with moderate disease, and recommended against thiopurines fo

65 ly age, especially for those with severe and moderate disease, and that BMI is an important, potentia

66 ons in more severe disease; phototherapy for moderate disease; and systemic agents including photoche

67 -618-DDC-ABD, and the animals developed only moderate disease as assessed by a near-normal clinical s

68 ic analysis of the serum of 21 patients with moderate disease at admission which progressed to severe

69 +/- 15.8, P < 0.001) and had generally mild-moderate disease at baseline (65.7% and 71% vs. 52%, P <

70 We identify a major shift between mild and moderate disease, at which point elevated inflammatory s

71 action was elevated in patients with mild-to-moderate disease burden but decreased in those with the

72 onists in hospitalized patients with mild-to-moderate disease, but IL-6 antagonists may be beneficial

73 thropoiesis, or hemoglobin between severe or moderate disease, but multiple linear regression showed

74 za delivered via multiple routes experienced moderate disease characterized by consistent viral shedd

75 but were also elevated in untreated, mild-to-moderate disease compared with healthy control subjects.

76 ve immune responses in individuals who had a moderate disease course, whereas those with severe disea

77 when compared with controls, whereas mild-to-moderate disease does not suppress contact sensitization

78 ) had mild disease (EASI 7), 120 (32.7%) had moderate disease (EASI >7 and 21), and 70 (19.1%) had se

79 people with no or mild disease annually and moderate disease every 6 months-yielded large difference

80 In contrast, individuals with moderate disease exhibited delayed responses that ultima

81 Women who have a mild to moderate disease flare while on optimized 5-ASA or thiop

82 In mild-moderate disease, for participants at or above the media

83 Mild and moderate disease forms seem to have a good outcome.

84 Even patients with mild/moderate disease frequently suffer adverse effects from

85 ession patterns: whereas patients displaying moderate disease had elevated expression of classical pa

86 ape in the lung tissue of patients with mild-moderate disease has not been well characterized at the

87 Outpatient therapies for mild-to-moderate disease have reduced hospitalizations and death

88 conversion of severe hemophilia B to mild or moderate disease in 6 adult males who underwent intraven

89 Second- and third-wave viruses caused moderate disease in ferrets, transmitted efficiently to

90 evere hemophilia A in some patients and mild/moderate disease in others.

91 increase of SMN levels and rescues severe to moderate disease in SMA mice.

92 es following challenge also indicated a more moderate disease in the vaccinated animals.

93 from asthmatic subjects with stable mild and moderate disease is an artifact of tissue sampling and i

94 ds in the treatment of patients with mild to moderate disease is less clear.

95 ad greater protein excretion than those with moderate disease (< or = 10 cysts; n = 49) (4.4+/-0.5 ve

96 This study suggests that moderate disease may provide the most effective setting

97 30 patients with severe and 63 patients with moderate disease (median age, 74 d; range, 9-297 d).

98 Within this stressed plasma environment at moderate disease, multiple unusual immune cell phenotype

99 Being distinct from mild and moderate disease, new insights into the immunopathogenes

100 In moderate disease, no independent predictors of hepcidin

101 ere complications than patients with mild or moderate disease (odds ratio [OR], 3.6; 95% CI, 1.4-8.9;

102 ease at baseline, those who reported mild or moderate disease on follow-up had significantly greater

103 ster infection (odds ratio [OR] = 4.0), mild/moderate disease (OR = 4.8), severe/critical disease (OR

104 P < .001) and were elevated in patients with moderate disease (OR, 1.50; 95% CI: 1.22, 1.84; P = .001

105 on can cause asymptomatic infection, mild to moderate disease, or severe disease resulting in organ d

106 nfected with influenza virus display mild-to-moderate disease phenotypes and recover within a few wee

107 Subjects with mild to moderate disease (PPC-II to PPC-III) showed mild/moderat

108 doses are economically optimal under low or moderate disease pressure, or where other control measur

109 effectiveness in population groups with low/ moderate disease prevalence (< or =70%); as expected, di

110 Viral evolution in individuals with rapid or moderate disease progression showed selection favoring n

111 psoriasis severity in patients with mild to moderate disease receiving stable topical therapy.

112 nucleotide polymorphisms (SNPs) have weak-to-moderate disease risks, genetic risk prediction models b

113 sease (CAD angiographic score of 0), mild-to-moderate disease (score of 1 to 3), and severe disease (

114 The cost per case for mild to moderate disease, severe disease, and critically ill was

115 ID-19 infection, 50% of patients experienced moderate disease severity and 10.5% were hospitalized.

116 Ataxia (SARA) points/year], not exceeding a moderate disease severity even in advanced stages (maxim

117 toms for 5 or more years, and presented with moderate disease severity in the OFF state [Hoehn and Ya

118 When moderate disease severity was confirmed, maximal oxygen

119 -confirmed Lassa fever patients with mild to moderate disease severity were invited to participate in

120 these 106 patients, 101 (95.3%) had mild-to-moderate disease severity, with FEV(1)%p greater than 40

121 5 days, and the SAP6 rescuant reestablished moderate disease severity.

122 ported high disease visibility and 50.5% had moderate disease severity.

123 roduced protein derived from tick saliva, in moderating disease severity.

124 Moderate disease showed retina-wide rod > cone dysfuncti

125 rough mild cognitive impairment to early and moderate disease stages).

126 x, Stanford class, and incidence of at least moderate disease (Stanford class > or = 3) were measured

127 s" (PaO 2 45.0 mm Hg; -1.0 mm Hg/year); and "moderate disease, steady decliners" (PaO 2 65.5 mm Hg; -

128 old greater in patients with asymptomatic or moderate disease than in those with severe disease.

129 The mixed-effects model shows that eyes with moderate disease that fail to achieve their target IOP e

130 gether, the rhesus macaque recapitulates the moderate disease that has been observed in the majority

131 However, the BCa11-3 mutant produced moderate disease that was significantly less severe than

132 gh most young individuals experience mild to moderate disease, there are concerns of long-term advers

133 g those regulating IRF1 and IRF7, whereas in moderate disease, these classical antiviral signals dimi

134 of motor control in individuals with mild to moderate disease through experience-dependent neuroplast

135 The distinction of severe and moderate disease was most reliant on the depletion of na

136 that of seasonal influenza viruses, mild-to-moderate disease was observed in infected mice and ferre

137 35% predicted), and 11 patients with mild to moderate disease were studied.

138 Thirty-six patients (48%) had moderate disease, whereas 39 patients (52%) had severe d

139 years, respectively, were estimated to have moderate disease, which highlights the potential benefit

140 would change when subjects improved to mild-moderate disease with controller medication treatment.

141 moderate-severe asthma who improved to mild-moderate disease with controller treatment, rescue beta-

142 esents an important strategy to consider for moderating diseases with altered endothelial integrity,

143 iagnostic challenge in patients with mild to moderate disease, with current imaging modalities being